Captor Therapeutics Sa · GPW:CTX
Captor Therapeutics Sa — Investor Day (May 2022)
28 slides from Captor Therapeutics Sa's investor day presentation, May 18, 2022
Slide 1: Investor Day Captor Therapeutics
INVESTOR DAY Captor Therapeutics the most innovative company on the WSE* 1 18th May 2022 * CT was awarded the title of Stock Exchange Company of the Year in the Innovation category by Puls Biznesu
Slide 2: Legal notice
Legal notice This document and the information contained herein (unless otherwise indicated) have been prepared by Captor Therapeutics S.A. (the “Issuer”) solely for informational purposes. For this notice, the presentation that follows shall mean and include the slides that follow, the oral present
Slide 3: Captor Therapeutics – key developments
Captor Therapeutics – key developments Serial announcements of in-vivo data OptigradeTM platform ✓ CT-01: GSPT1, SALL4 + undisclosed target Captor’s unique capacities in Biophysics, • Molecular Glue with unique degradation Structural Biology and Chemistry are profile bearing fruit • Strong efficacy
Slide 4: Global Landscape – TPD Technology
GLOBAL LANDSCAPE – TPD TECHNOLOGY 4
Slide 5: Targeted Protein Degradation – a revolution
Global landscape Targeted Protein Degradation – a revolution Targeted Protein Degradation (TPD) opens Value of equity raised in Biotech a new chapter in Pharmaceuticals $140 • TPD drugs have the potential to address unmet medical needs $120 with a unique mode of action inaccessible to classic approa
Slide 6: Biopharmaceutical market to reach $525 billion by 2025
Global landscape Biopharmaceutical market to reach $ 525 billion by 2025* • TPD, like other biopharmaceutical sectors, benefits from the scientific developments in biology • But TPD has a unique position compared to other breakthrough modalities: it uses small molecule drugs • First generation molec
Slide 7: Captor's Positioning
CAPTOR’S POSITIONING Poa Captor . Therapeutics
Slide 8: Vision – become a world-leading drug discovery company based on TPD
Captor’s positioning Vision – become a world-leading drug discovery company based on Targeted Protein Degradation Wroclaw, Polska • Based in Wroclaw (Poland) and Basel (Switzerland) • Significantly oversubscribed IPO in April 2021 Basel, • Strong support of non-dilutive funding from NCBR Szwajcaria
Slide 9: An experienced leadership team
Captor’s positioning An experienced leadership team LEADERSHIP TEAM Tom Shepherd, Ph.D. Michal Walczak, Ph.D. Radoslaw Krawczyk Sylvain Cottens, Ph.D. Chief Executive Officer Chief Scientific Officer Chief Financial Officer Co – founder – SVP Chemistry • Chief Executive Officer • Ph.D. ETH Zurich, •
Slide 10: Company pipeline projects
Captor’s Captor’s positioning positioning Company pipeline projects # Indications Modality Discovery Preclinical* IND Filing FIH** FIH** Hepatocellular CT-01 carcinoma MG Autoimmunity CT-02 Liquid tumors MG 2023 Liquid & solid CT-03 tumours BID MCL-1 target Colorectal CT-04 cancer BID Autoimmunity C
Slide 11: Captor's Optigrade platform
Captor’s positioning Captor’s OptigradeTM platform Molecular Glues Platform differentiation Molecular Small molecules with good drug Glues • Lead compounds both in properties that stabilize the interaction molecular glues and bifunctional between the E3 Ligase and the target degraders • Structure-ba
Slide 12: Principle of Targeted Protein Degradation
Captor’s positioning Principle of Targeted Protein Degradation 12 Business Business Use Only | Do not use without written Use Only consent of |Captor Do not Therapeutics use without written Inc. ©consent 2021 of Captor Therapeutics Inc. © 2022~ 12
Slide 13: Rationalization of Molecular Glue Discovery
Captor’s positioning Molecular Rationalization of Molecular Glue Discovery Glue ZnF Target Non-ZnF Target ZNF517 PLK kinases ZNF582 NIMA kinases ZNF653 PAK kinases IKZF1/3 GTPases CRBN PoI ZFP91 WD repeat IKZF2/4 Chaperones PATZ1 Phosphatases Sievers Q., Petzold G. et al. Science (2018) 362(6414) Mo
Slide 14: 2 drug candidates advancing towards the clinics
Captor’s positioning 2 drug candidates advancing towards the clinics Project: Project: CT-01 CT-03 Molecular Positioning: Bifunctional Positioning: Glues Unique degradation profile Degraders First-in-class MCL-1 degrader Main indication: Main indications: hepatocellular carcinoma blood cancers • Ant
Slide 15: Broad Applicability of the CT-02 Molecular Glues
Captor’s Captor’s positioning positioning Broad Applicability of the CT-02 Molecular Glues Project: CT-02 Main indication: Autoimmunity, Oncology, CNS CNS (AZ) Molecular Glues • According to forecasts by the World Health Organization, the number of new leukemia cases worldwide will increase from abo
Slide 16: Underexplored Opportunities in Novel Ligases
Captor’s positioning Underexplored Opportunities in Novel Ligases New Ligases • There are ~600 different E3 ubiquitin ligases • So far, ligands identified to only a few E3 ligases • All clinical-stage degraders based on CRBN (and one on VHL) Families E3 ubiquitin ligases 16 Business Business Use Onl
Slide 17: Novel E3 Ligase with Unique Expression Profile
Captor’s positioning Novel E3 Ligase with Unique Expression Profile New Ligases kDa 200 116.3 97.4 66.3 55.4 Novel E3 Ligase 36.5 Novel E3 Ligase Offers Application in Cancer without affecting healthy cells 17 Business Business Use Only | Do not use without written Use Only consent of |Captor Do not
Slide 18: Summary of scientific discovery
Captor’s positioning Summary of scientific discovery Highly advanced pre-clinical pipeline with spectacular results Rationalization of molecular glue discovery engine Identification of novel E3 ligases with greatly attractive properties 18 Business Business Use Only | Do not use without written Use
Slide 19: Financial Results
FINANCIAL RESULTS Poa Captor . Therapeutics
Slide 20: Full year on the Stock Exchange
Captor for investors Full year on the Stock Exchange Financing from the IPO in April 2021, allowed us to accelerate business and corporate processes We would like to thank our shareholders for their trust and support Proceeds from the IPO opened a new phase of the Company’s development and will allo
Slide 21: Selected consolidated financial data
Captor for investors Selected consolidated financial data Revenues and financial results (PLN thousands) Consolidated statement of financial position (PLN, M) 130,6 FY 2021 FY 2020 124,2 Research and development income 3 986 - Cost of services sold 741 - Net loss -32 572 - 12 694 13,0 12,5 13,3 16,4
Slide 22: Strong balance sheet and investments as foundation for further development
Captor for Strong balance sheet and investments investors as foundation for further development 1. HIGHLY QUALIFIED PERSONNEL (Data as of 31/12/2021) Number of employees 98 22% increase in research Number of research workers 87 workers in 2021 Percentage of scientists with PhD 49% 2. INCREASED FIXED
Slide 23: Plans for the Future
PLANS FOR THE FUTURE Captor KK Therapeutics”
Slide 24: Executive summary
Plans for the future Executive summary Major in-vivo project milestones in CT-01, Continuing to build a strong international CT-03 - molecular targets announced, team drug candidates CT-02 makes breakthrough with potent Puls Biznesu Award - the most innovative degraders against an autoimmune target
Slide 25: Near term objectives and milestones
Plans for the future Near term objectives and milestones WORKING TO DEVELOP PARTNERSHIPS WITH PLATFORM DRUG CANDIDATES OTHER ENTITIES DEVELOPMENT ▶ Announce additional in-vivo ▶ Continuing the Sosei Heptares ▶ Advancing our new ligase results in our pipeline projects collaboration ligands to develop
Slide 26: Q&A Session
Q&A SESSION Captor KK Therapeutics”
Slide 27: Captor Therapeutics S.A contact details
Captor Therapeutics S.A ul. Duńska 11 54-427 Wrocław, Polska Captor Therapeutics GmbH Gewerbestrasse 24 4123 Allschwil, Szwajcaria IR Contact: Marta Święcicka m.swiecicka@captortherapeutics.com Media and IR Contact: captortherapeutics@pov.pl 27
Slide 28: Projects are co-financed by the European Regional Development Fund
Projects are co-financed by the European Regional Development Fund: Discovery and development of a new clinical drug candidate for the eradication of cancer stem cell in the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor (POIR.01.01.01-00-0740/19) Discov